Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Saved in:
Bibliographic Details
Published in:Actas dermo-sifiliográficas (English ed.) Vol. 113; no. 7; pp. 674 - 684
Main Authors: Serra-Baldrich, E, Santamaría-Babí, L F, Francisco Silvestre, J
Format: Journal Article
Language:English
Spanish
Published: 01-07-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1578-2190
DOI:10.1016/j.ad.2021.12.014